Nirmatrelvir/Ritonavir Fails To Shorten COVID-19 Symptom Duration For People At Standard Risk And Vaccinated At-Risk People, Study Finds

MedPage Today (4/3, Kahn) reports, “Nirmatrelvir/ritonavir (Paxlovid) failed to shorten COVID-19 symptom duration among people at standard risk for severe COVID-19 and among vaccinated people with at least one risk factor for severe disease, according to final results of the phase II/III EPIC-SR trial.” Among these populations, “the median time to alleviation of COVID-19 symptoms was 12 days, compared with 13 days in patients who took a placebo (P=0.60), reported” researchers “in the New England Journal of Medicine.”